Since one of the primary pathophysiologies of obesity-related hypertension is through activation of the RAAS system, ACE inhibitors or angiotensin receptor blockers (ARBs) may be appropriate as an initial agent for pharmacologic therapy for hypertension in children. Here, ACE is linked to obesity disorder.